Search

everythinglearnresearchcommunity

for

Search:↓

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

A 17-year-old is experiencing rapid hair loss from NW1.5 to NW3 in six months and feels dermatologists are unhelpful. They are using Minoxidil (Rogaine) and seeking advice on application.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

Hair loss treatment progress after 8 months using finasteride, minoxidil, nizoral, and dermarolling. Discussion includes positive feedback on results and question about needle replacement for dermarolling.

The user experienced significant hair regrowth using a daily regimen of finasteride, minoxidil foam, and scalp massages over three years, with no side effects from finasteride. They noticed new hair growth within 1-2 months and have maintained their results, sharing their experience to help others.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

A 23-year-old male shared his 11-month progress using 1.25mg finasteride every other day and Nizoral/Dermazole, reporting reduced hair fall and new hair growth without major shedding. Users discussed the risks of finasteride for younger individuals and suggested consulting a doctor, with some recommending minoxidil as an alternative.

A user questioning if they've lost any hair between 2020 and 2023 without using any treatments. They also inquire if a doctor can determine hair loss just by looking, recalling a past suggestion of platelet rich plasma treatment.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

Nicotinamide Riboside (NR) significantly reduced hair loss for the user. They found science.bio's NR to be effective, unlike other brands.

The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user reported maintaining hair with finasteride, minoxidil, microneedling, Nizoral, vitamins, and lifestyle changes over 18 months, and switched to topical finasteride due to side effects from the oral form. They also improved their microneedling technique.

Hair loss progress update: finasteride, minoxidil, dermaroll, nizoral. Dermaroll depth 1.5mm, 3 times a week.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The user has been using minoxidil and finasteride once a day, derma rolling once a week, and washing with nizoral once a week since January 2023. They have seen good progress on their hairline.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

A user is considering a hair transplant in a "mohawk" pattern with scalp micropigmentation (SMP) on the sides and back, questioning its feasibility and appearance. Others discuss donor region quality, potential scarring, and alternative treatments like dutasteride and RU58841.

A user shared their positive experience with a non-surgical hair replacement system, detailing the purchase and maintenance process, including using Walker Lace Front Support Tape and various adhesives. They found the system secure and undetectable, allowing them to engage in active pursuits without issues.

Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.

The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.

The conversation discusses the use of RU58841 for hair loss, focusing on its side effects, standardization issues, and user experiences. The user also inquires about the use of other treatments like minoxidil, finasteride, and microneedling.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

User shared a 10-month update after a 4000-graft hair transplant, using finasteride, minoxidil, hair density shampoos, hair oils, and vitamins. Replies suggest patience as crown growth can take up to 18 months.